• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过激光捕获显微切割定义宫颈上皮内瘤变中的人乳头瘤病毒基因型,支持使用 HPV16/18 和 FAM19A4/miR124-2 甲基化进行自我样本的反射性分类。

Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.

机构信息

DDL Diagnostic Laboratory, Rijswijk, the Netherlands.

Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands.

出版信息

Gynecol Oncol. 2018 Nov;151(2):311-318. doi: 10.1016/j.ygyno.2018.09.006. Epub 2018 Sep 13.

DOI:10.1016/j.ygyno.2018.09.006
PMID:30219239
Abstract

OBJECTIVE

HPV16/18 genotyping and detection of hypermethylation of human cell genes involved in cervical oncogenesis have shown promising results in triage of high-risk HPV (hrHPV)-screen positive women on cervical smears. These tests can be performed on self-samples, which contain cervical and vaginal cells. We studied whether a self-sample represents the hrHPV type causing the worst cervical lesion and whether any differences in hypermethylation of FAM19A4/miR124-2 exist between CIN lesions caused by different hrHPV types. These results have important implications for reflex triage of self-samples.

METHODS

Correlation between genotype found on self-sample using GP5+/6+-PCR-EIA-LMNX and causative hrHPV genotype in the worst lesion on histology was studied using laser capture microdissection (LCM)-SPF10-PCR (N = 152). Hypermethylation of FAM19A4/miR124-2 in the self-sample was tested in a quantitative methylation specific PCR and compared between lesions caused by HPV16/18 and other hrHPV genotypes.

RESULTS

Causative hrHPV genotype of the worst lesion (CIN1, CIN2, CIN3, invasive cervical cancer) was detected on self-sample in 93.4%. HPV16 was the most frequently found genotype on self-sampling (39.2%, 73/186) and causative genotype in CIN3+ (51.4%, 38/74, all detected on self-sample). There were no differences in the percentages of positive FAM19A4/miR124-2 methylation assays between lesions caused by HPV16/18 (73.8% in CIN3+) or other hrHPV genotypes (66.7% in CIN3+) (p = 0.538).

CONCLUSIONS

Our results show that hrHPV genotypes found on self-sample were a good representation of hrHPV in the worst CIN lesion and that methylation testing on self-sample for detection of CIN3+ was not significantly different between lesions caused by HPV16/18 and other hrHPV genotypes.

摘要

目的

HPV16/18 基因分型和检测参与宫颈癌发生的人类细胞基因的超甲基化,在宫颈涂片上 HPV 高危型(hrHPV)阳性的女性中进行分流显示出了良好的效果。这些测试可以在自采样上进行,自采样包含宫颈和阴道细胞。我们研究了自采样是否代表引起最严重宫颈病变的 hrHPV 类型,以及不同 hrHPV 类型引起的 CIN 病变之间 FAM19A4/miR124-2 超甲基化是否存在差异。这些结果对于自采样的反射性分流具有重要意义。

方法

使用激光捕获微切割(LCM)-SPF10-PCR(N=152)研究了使用 GP5+/6+-PCR-EIA-LMNX 在自采样上发现的基因型与组织学上最严重病变的致病 hrHPV 基因型之间的相关性。在定量甲基化特异性 PCR 中测试了自采样中 FAM19A4/miR124-2 的超甲基化,并比较了 HPV16/18 和其他 hrHPV 基因型引起的病变之间的差异。

结果

在 93.4%的情况下,自采样上检测到最严重病变(CIN1、CIN2、CIN3、浸润性宫颈癌)的致病 hrHPV 基因型。自采样中最常见的 HPV16 基因型为 39.2%(73/186),CIN3+中最常见的致病基因型为 51.4%(38/74,均在自采样中检测到)。HPV16/18(CIN3+中为 73.8%)或其他 hrHPV 基因型(CIN3+中为 66.7%)引起的病变中 FAM19A4/miR124-2 甲基化检测阳性率无差异(p=0.538)。

结论

我们的结果表明,自采样上发现的 hrHPV 基因型很好地代表了最严重 CIN 病变中的 hrHPV,并且自采样上用于检测 CIN3+的甲基化检测在 HPV16/18 和其他 hrHPV 基因型引起的病变之间没有显著差异。

相似文献

1
Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.通过激光捕获显微切割定义宫颈上皮内瘤变中的人乳头瘤病毒基因型,支持使用 HPV16/18 和 FAM19A4/miR124-2 甲基化进行自我样本的反射性分类。
Gynecol Oncol. 2018 Nov;151(2):311-318. doi: 10.1016/j.ygyno.2018.09.006. Epub 2018 Sep 13.
2
Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.用于检测HPV阳性女性宫颈(癌前)病变的基于灌洗和刷取的自我样本的FAM19A4/mir124-2 DNA甲基化检测的验证
Gynecol Oncol. 2016 May;141(2):341-347. doi: 10.1016/j.ygyno.2016.02.012. Epub 2016 Mar 3.
3
Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.在细胞学筛查转诊人群中,使用 hrHPV 基因分型和甲基化标志物可靠地区分 CIN3+的女性。
Int J Cancer. 2019 Jan 1;144(1):160-168. doi: 10.1002/ijc.31787. Epub 2018 Nov 18.
4
Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study.甲基化标志物 FAM19A4 和 miR124-2 作为原发性人乳头瘤病毒筛查阳性女性的分流策略:一项大型欧洲多中心研究。
Int J Cancer. 2021 Jan 15;148(2):396-405. doi: 10.1002/ijc.33320. Epub 2020 Oct 21.
5
Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).比较FAM19A4甲基化分析、细胞学检查和HPV16/18基因分型在妇科门诊高危HPV阳性女性中检测宫颈(癌前)病变的性能(COMETH研究)。
Int J Cancer. 2016 Feb 15;138(4):992-1002. doi: 10.1002/ijc.29824. Epub 2015 Sep 14.
6
FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years.FAM19A4/miR124-2 甲基化检测及 HPV 阳性 30 岁以下女性的 HPV16/18 基因分型。
Clin Infect Dis. 2023 Feb 8;76(3):e827-e834. doi: 10.1093/cid/ciac433.
7
FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.FAM19A4/miR124-2 甲基化在浸润性宫颈癌中的研究:一项回顾性的、全球性的横断面研究。
Int J Cancer. 2020 Aug 15;147(4):1215-1221. doi: 10.1002/ijc.32614. Epub 2019 Sep 9.
8
Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis.HPV 阳性女性经 FAM19A4/miR124-2 甲基化分析进行分流后的长期 CIN3+风险。
Gynecol Oncol. 2019 Aug;154(2):368-373. doi: 10.1016/j.ygyno.2019.06.002. Epub 2019 Jun 8.
9
Complementarity between miRNA expression analysis and DNA methylation analysis in hrHPV-positive cervical scrapes for the detection of cervical disease.miRNA 表达分析与 DNA 甲基化分析在 hrHPV 阳性宫颈刮片中用于宫颈疾病检测的互补性。
Epigenetics. 2019 Jun;14(6):558-567. doi: 10.1080/15592294.2019.1600390. Epub 2019 Apr 8.
10
Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping.甲基化估计了细胞学和 HPV16/18 基因分型结果不一致的 HPV 感染女性的癌前病变风险。
Clin Epigenetics. 2019 Oct 12;11(1):140. doi: 10.1186/s13148-019-0743-9.

引用本文的文献

1
The triage role of cytological DNA methylation in women with non-16/18, specifically genotyping high-risk HPV infection.细胞学DNA甲基化在非16/18型、特别是基因分型高危型人乳头瘤病毒感染女性中的分诊作用。
Br J Cancer. 2025 Apr 10. doi: 10.1038/s41416-025-03005-5.
2
Triage performance of PAX1/JAM3 in opportunistic cervical cancer screening of non‒16/18 human papillomavirus-positive women: a multicenter prospective study in China.PAX1/JAM3 在非 16/18 型人乳头瘤病毒阳性妇女机会性宫颈癌筛查中的诊断效能:中国多中心前瞻性研究。
Clin Epigenetics. 2024 Aug 16;16(1):108. doi: 10.1186/s13148-024-01731-w.
3
Assessing the risk of cervical neoplasia in the post-HPV vaccination era.
评估 HPV 疫苗接种后宫颈上皮内瘤变的风险。
Int J Cancer. 2023 Mar 15;152(6):1060-1068. doi: 10.1002/ijc.34286. Epub 2022 Oct 10.
4
Epigenetic and Transcriptomic Regulation Landscape in HPV+ Cancers: Biological and Clinical Implications.人乳头瘤病毒阳性癌症中的表观遗传和转录组调控格局:生物学及临床意义
Front Genet. 2022 Jun 14;13:886613. doi: 10.3389/fgene.2022.886613. eCollection 2022.
5
DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population.DNA 甲基化标志物作为一种甄别试验,用于早期识别中国人群中的宫颈病变。
Int J Cancer. 2021 Apr 1;148(7):1768-1777. doi: 10.1002/ijc.33430. Epub 2020 Dec 20.
6
DNA Methylation and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment.宫颈癌中的DNA甲基化与羟甲基化:诊断、预后与治疗
Front Genet. 2020 Apr 9;11:347. doi: 10.3389/fgene.2020.00347. eCollection 2020.
7
Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16/18 and cytology.评价一种甲基化分类器,用于预测 HPV16/18 和细胞学检查结果异常的女性中的癌前病变。
Clin Epigenetics. 2020 Apr 21;12(1):57. doi: 10.1186/s13148-020-00849-x.